Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...

ImmunityBio (NasdaqGS:IBRX) completed enrollment early in its pivotal Phase 2 bladder cancer trial for ANKTIVA. Interim analysis showed a statistically significant improvement in complete response ...

After partnering with Depend last year following his bladder cancer surgery, Colorado head coach Deion Sanders brought his story to life in his first commercial for the company.

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

UroGen Pharma's ZUSDURI is positioned for accelerated adoption following a permanent J-Code in 2026. Read more on URGN stock and why it is a Buy.

An aggressive bladder cancer diagnosis made 2025 one of the toughest years of Deion Sanders’ life. Coach Prime underwent a ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

What Is Transurethral Resection of Bladder Tumor (TURBT)? If you have bladder cancer or suspected bladder cancer, your doctor has probably told you that you need a transurethral resection of the ...

Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...